Journal article · 2026 · Open access

Advances in the Application of PROTAC Technology in Cancer Therapy

Yuting Fu

Theoretical and Natural Science, 184(1), 58–64 · Published 4 August 2026 · DOI 10.54254/2753-8818/2026.hz35789

Open PDFView at the publisherCite this paper

In brief

“Advances in the Application of PROTAC Technology in Cancer Therapy” is a 2026 journal article by Yuting Fu, published in Theoretical and Natural Science. OpenAlex counts 0 citations as of 19 November 2026. It is open access under a CC BY licence: the full text is free to read at Theoretical and Natural Science.

Citations
0
References
14
Authors
1

Abstract

Traditional small-molecule anticancer inhibitors primarily block single protein activities and are vulnerable to mutation-mediated drug resistance. Proteolysis-targeting chimera (PROTAC) technology induces the ubiquitin-proteasome-dependent clearance of oncogenic proteins and provides a promising new strategy for precision cancer therapy. This paper summarizes the molecular basis, degradation mechanism, design principles, and translational progress of PROTAC degraders in cancer treatment. PROTACs consist of a target ligand, an E3 ubiquitin ligase ligand and a connecting linker, and they exert unique event-driven antitumor effects by inducing ternary complex formation and target ubiquitination. Representative ER, AR, BTK, BCL-xL, and BRD4 degraders have shown promising preclinical or clinical activity, especially in drug-resistant tumors. Current challenges include poor oral pharmacokinetic properties, incomplete tumor selectivity, uncertain long-term safety, and emerging resistance mechanisms related to ubiquitin signaling. Optimized ligand-linker design, tumor-selective E3 ligases, prodrug strategies and biomarker-guided clinical trials are expected to greatly promote the clinical development of PROTAC-based anticancer therapies.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Fu, Y. (2026). Advances in the Application of PROTAC Technology in Cancer Therapy. Theoretical and Natural Science, 184(1), 58–64. https://doi.org/10.54254/2753-8818/2026.hz35789

MLA 9

Fu, Yuting. “Advances in the Application of PROTAC Technology in Cancer Therapy.” Theoretical and Natural Science, vol. 184, no. 1, 2026, pp. 58–64. https://doi.org/10.54254/2753-8818/2026.hz35789.

Chicago

Fu, Yuting. 2026. “Advances in the Application of PROTAC Technology in Cancer Therapy.” Theoretical and Natural Science 184 (1): 58–64. https://doi.org/10.54254/2753-8818/2026.hz35789.

Harvard

Fu, Y. (2026) ‘Advances in the Application of PROTAC Technology in Cancer Therapy’, Theoretical and Natural Science, 184(1), pp. 58–64. doi:10.54254/2753-8818/2026.hz35789.

IEEE

Y. Fu, “Advances in the Application of PROTAC Technology in Cancer Therapy,” Theoretical and Natural Science, vol. 184, no. 1, pp. 58–64, 2026, doi: 10.54254/2753-8818/2026.hz35789.

BibTeX

@article{fu2026advances,
  title     = {{Advances in the Application of PROTAC Technology in Cancer Therapy}},
  author    = {Fu, Yuting},
  journal   = {Theoretical and Natural Science},
  year      = {2026},
  volume    = {184},
  number    = {1},
  pages     = {58--64},
  doi       = {10.54254/2753-8818/2026.hz35789},
  url       = {https://doi.org/10.54254/2753-8818/2026.hz35789}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors

  • PROTACs
  • ubiquitin-proteasome system
  • protein degradation
  • E3 ubiquitin ligase
  • linker design
  • drug resistance
  • estrogen receptor
  • androgen receptor

Work with this paper

Most-cited papers in Biochemistry, Genetics and Molecular Biology

All highly cited Biochemistry, Genetics and Molecular Biology papers

Questions about this paper

How do I cite this paper in APA style?

Fu, Y. (2026). Advances in the Application of PROTAC Technology in Cancer Therapy. Theoretical and Natural Science, 184(1), 58–64. https://doi.org/10.54254/2753-8818/2026.hz35789

How many times has this paper been cited?

0 times, according to OpenAlex on 19 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Theoretical and Natural Science: sign in and open the PDF from this page.

Who wrote this paper?

Yuting Fu.

What is the DOI of this paper?

10.54254/2753-8818/2026.hz35789, permanently at https://doi.org/10.54254/2753-8818/2026.hz35789. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 19 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.